Management of Methotrexate Toxicity
Immediately administer leucovorin (folinic acid) as the primary antidote for methotrexate toxicity, with dosing and duration guided by serum MTX levels and clinical status; glucarpidase should be reserved for life-threatening cases with delayed clearance and renal impairment when leucovorin alone is insufficient.
Immediate Recognition and Initial Management
Early Intervention is Critical
Time is the most critical factor—leucovorin effectiveness decreases dramatically as the interval from MTX exposure increases 1, 2. Symptoms may take 6-23 days to manifest and include mucositis, fever, diarrhea, erythema, ulceration, and rarely cutaneous necrolysis 1.
First-Line Treatment: Leucovorin (Folinic Acid)
For acute overdose (within 1 hour):
- Administer activated charcoal if ≥1 mg/kg MTX ingested 1
- Admit to hospital immediately
- Measure serum MTX levels at least 4 hours post-ingestion 1
Leucovorin dosing:
- Initial dose: up to 100 mg/m² IV if MTX level unknown 1
- Subsequent doses: every 6 hours (oral or IV) 1
- Continue until MTX levels <0.05 µmol/L OR hematological abnormalities normalize AND mucosal ulceration heals 1
- Most effective when initiated within hours; doubtful efficacy if started >24 hours post-exposure 1
Critical caveat: Do NOT administer leucovorin within 2 hours before or after glucarpidase, as leucovorin is a substrate for glucarpidase and will be degraded 2.
Supportive Measures (Concurrent with Leucovorin)
Renal Protection
- Aggressive hydration to improve renal elimination 1, 2
- Urine alkalinization with sodium bicarbonate to prevent MTX precipitation in renal tubules 1, 2
- Monitor serum creatinine, urine output, and serum MTX concentrations 3
Bone Marrow Support
For toxic bone marrow suppression, use filgrastim 5 µg/kg subcutaneously daily to accelerate myeloid recovery 1.
When to Escalate: Glucarpidase
Glucarpidase is indicated specifically for:
- Toxic MTX concentrations with delayed clearance due to impaired renal function 2
- High-dose MTX toxicity with renal injury when leucovorin is insufficient 4
- Intrathecal MTX poisoning (primary indication) 4
Mechanism: Decreases serum MTX by 90-95% within 15 minutes through enzymatic degradation 4.
Important limitations:
- Significant cost and limited availability 4
- Rarely indicated in high-dose MTX toxicity unless renal injury present 4
- Remember the 2-hour leucovorin exclusion window 2
Alternative Clearance Methods
Hemodialysis
When glucarpidase is unavailable, acute intermittent hemodialysis using high-flux dialyzers can effectively clear MTX 2. Recent evidence supports continuous renal replacement therapy (CRRT) as a viable salvage option for life-threatening toxicity with AKI when glucarpidase is unavailable 5.
Standard hemodialysis and peritoneal dialysis are generally ineffective 2.
Special Scenarios
Intrathecal Overdose
Requires intensive management 2:
- High-dose systemic leucovorin
- Alkaline diuresis
- Rapid CSF drainage
- Ventriculolumbar perfusion
- Consider intrathecal glucarpidase (published case reports support this) 2
Chronic Low-Dose Toxicity
Recent data shows organ dysfunction can occur after as few as 3 consecutive days or cumulative doses ≥37.5 mg when taken daily instead of weekly 6. No patient developed toxicity with <3 days or <37.5 mg total 6.
Monitoring for Complications
Watch for high mortality risk factors 1:
- Sepsis/septic shock
- Renal failure
- Aplastic anemia
- Monitor carefully and treat infections aggressively
Common Toxicities to Monitor
- Hematologic: Leukopenia, thrombocytopenia, anemia, pancytopenia 2
- Gastrointestinal: Mucositis, stomatitis, oral ulceration, GI bleeding 2
- Renal: AKI occurs in 2-12% of high-dose cases 3
- Hepatic: Elevated aminotransferases 6
Prevention Pitfall
The most common error is daily instead of weekly dosing due to patient confusion 6. To prevent this 1:
- Prescribe only 2.5 mg tablets (avoid confusion between 2.5 mg and 10 mg tablets)
- Write dose in UPPERCASE letters to avoid decimal point errors
- Explicitly counsel patients on once-weekly dosing